RecruitingPhase 3NCT06867991

Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis

Studying Autoimmune encephalitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The First People's Hospital of Changzhou
Intervention
Ofatumumab combined with daratumumab(drug)
Enrollment
200 enrolled
Eligibility
12 years · All sexes
Timeline
20242027

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06867991 on ClinicalTrials.gov

Other trials for Autoimmune encephalitis

Additional recruiting or active studies for the same condition.

See all trials for Autoimmune encephalitis

← Back to all trials